<DOC>
	<DOCNO>NCT00612612</DOCNO>
	<brief_summary>Obatoclax may stop growth chronic lymphocytic leukemia block blood flow cancer block enzyme need cell growth . Drugs use chemotherapy , fludarabine , work different way stop growth cancer cell , either kill cell stop dividing . Monoclonal antibody , rituximab , block cancer growth different way . Some block ability cancer cell grow spread . Others find cancer cell help kill carry cancer-killing substance . Giving obatoclax together fludarabine rituximab may kill cancer cell . This phase I trial study side effect best dose obatoclax give together fludarabine rituximab treat patient B-cell chronic lymphocytic leukemia .</brief_summary>
	<brief_title>Obatoclax , Fludarabine , Rituximab Treating Patients With Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : I . To determine maximum tolerate dose obatoclax mesylate combination fludarabine phosphate-rituximab ( FR ) patient relapse chronic lymphocytic leukemia . SECONDARY OBJECTIVES : I . To evaluate toxicity obatoclax mesylate combination FR patient population . II . To determine objective response rate progression-free survival obatoclax mesylate combination FR . III . To correlate level anti-apoptotic Bcl-2 family member drug response . IV . To determine whether apoptosis induce via mitochondrial pathway response obatoclax mesylate enhance FR . OUTLINE : This dose-escalation study obatoclax mesylate . Patients receive obatoclax mesylate IV 3 hour day 1 3 , fludarabine IV 20-30 minute day 1-5 , rituximab IV 4 hour day 1 ( day 1 3 course 1 ) . Treatment repeat every 28 day 6 course absence disease progression unacceptable toxicity . Patients undergo peripheral blood collection correlative study . Samples analyzed expression pro- anti-apoptotic Bcl-2 family member western blot ; apoptosis induction measurement lymphocyte count , Annexin V staining , Caspase PARP cleavage ; activate Bax immunoprecipitation ; Bax promoter polymorphism PCR amplification direct sequencing . After completion study therapy , patient follow every 6 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis Bcell chronic lymphocytic leukemia ( BCLL ) prolymphocytic leukemia ( PLL ) arise CLL No de novo PLL Malignant B cell must coexpress CD5 CD19 CD20 Patients lack CD23 expression leukemia cell may ( 11 ; 14 ) cyclin D1 overexpression , rule mantle cell lymphoma Must document lymphocytosis &gt; 5,000/uL Must require therapy base follow criterion : Massive progressive splenomegaly and/or lymphadenopathy Anemia ( hemoglobin &lt; 11 g/dL ) thrombocytopenia ( platelet count &lt; 100,000/uL ) Presence weight loss &gt; 10 % precede 6month period NCI grade 2 3 fatigue Fevers &gt; 100.5 F night sweat &gt; 2 week without evidence infection Progressive lymphocytosis increase &gt; 50 % 2month period anticipate doubling time le 6 month Must receive least one prior therapy BCLL No known brain metastasis ECOG performance status ( PS ) 01 Karnofsky PS 70100 % Total bilirubin normal ( unless due Gilbert syndrome compensate hemolysis ) Life expectancy &gt; 3 month Creatinine normal Fertile patient must use effective contraception Not pregnant nursing Negative pregnancy test Any number prior therapy allow At least 1 year since prior fludarabine phosphaterituximab combination therapy No concurrent combination antiretroviral therapy HIVpositive patient No chemotherapy radiotherapy within past 4 week ( 6 week nitrosoureas mitomycin C ) No concurrent investigational agent AST ALT &lt; 2.5 time upper limit normal Recovered prior therapy History allergic reaction attribute compound similar chemical biologic composition obatoclax mesylate agent use study Active Coombs ' positive autoimmune hemolytic anemia Chronic active hepatitis B patient appropriate antiviral therapy ( e.g. , lamivudine , adefovir ) Other neurological disorder dysfunction history seizure disorder Uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia include QTc &gt; 450 msec Psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
</DOC>